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Nicolas Dulphy1,2,3, Jeannig Berrou1,3, Jose´ A. Campillo4,7, Martine Bagot4,5,6, Armand Bensussan4,5
and Antoine Toubert1,2,3
Sezary syndrome (SS) is a rare lymphoma characterized by the clonal expansion in the skin and in blood of
CD4þCD158kþ T cells. Natural killer (NK) activation against tumors in leukemia models is partly based on the
recognition of the target through the NKG2D/NKG2D ligands interactions. We analyzed ex vivo SS malignant
lymphocytes for the expression of the NKG2D ligands such as the major histocompatibility complex class I-
related molecules (MIC) A and B and the UL16 binding proteins (ULBP). The expressions of NKG2D, the natural
cytotoxicity receptors (NKp30, NKp44, and NKp46) and the activating receptor DNAM-1 were simultaneously
investigated on circulating patients NK and CD8þ nonmalignant lymphocytes. Interestingly, although at least
one of the NKG2D ligands was expressed on the circulating malignant lymphocytes of 9 out of 10 patients,
NKG2D was expressed on effector lymphocytes. We found that soluble MICA in patient’s sera was increased,
which may constitute a mechanism to escape the immune response. In vitro, SS tumor lymphocytes induced the
degranulation of perforin by the NKL cell line. More importantly, NKG2D expressed on SS patients NK cells is
functional and capable to induce degranulation. Altogether, these data could suggest that stimulating NK
function in SS patients may be a promising strategy to reduce tumor invasion.
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INTRODUCTION
Sezary syndrome (SS) is an orphan disease corresponding to
an advanced form of cutaneous T-cell lymphoma with
malignant T cells in peripheral blood derived from the skin-
invasive T-cell clone (Kim et al., 2005; Querfeld et al., 2005).
SS commonly displays the expansion of a CD45ROþCD4þ
clonal T-lymphocyte population expressing skin-homing
receptors such as CCR4 and CCR10 as well as the cutaneous
lymphocyte antigen. Moreover, we recently reported that
Sezary tumor clones are characterized by the expression on
the cell surface of the killer immunoglobulin-like receptor
(KIR) CD158k (Poszepczynska-Guigne et al., 2004), which
allows for the evaluation of the tumor burden (Ortonne et al.,
2006; Bahler et al., 2008). In addition, in some patients,
expression of KIR receptors CD158a and/or CD158b on
malignant CD4þ T cells with an unusual activating function
has also been reported (Marie-Cardine et al., 2007).
Immunity in SS demonstrates a severe defect in mounting a
Th1 response correlating with depressed IL-12 levels. The
addition of IL-12 in vitro to circulating lymphocytes from SS
patients can reverse this Th1 defect by stimulating IFN-g
production and natural killer (NK) cell activity (Rook et al.,
1995, 1996). In addition, IL-21 has recently been described
as a potent stimulator of NK and CD8þ T-cell activity in SS
peripheral blood lymphocytes without inducing a malignant
T-cell proliferation (Yoon et al., 2008).
Initially, NK cells were characterized by their ability to kill
tumor cells and their antitumor activity is now widely
accepted. Indeed, the anti-leukemia response by NK cells
has strictly been demonstrated in allogeneic hematopoietic
stem cell transplantation situations (Ruggeri et al., 2002).
NKG2D is a major activating receptor, expressed on NK and
CD8þ T cells, involved in tumor immunosurveillance
(Coudert and Held, 2006) and whose expression is increased
by IL-15 (Sutherland et al., 2006). It activates effector cells in
humans through the recognition of the major histocompat-
ibility complex-class I-related molecules A and B (MICA/B) or
by the UL16 binding proteins (ULBP) on target cells. NKG2D
ligands (NKG2D-L) are often overexpressed on tumor cells
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from various cytological origins, including chronic and acute
leukemia (Pende et al., 2002; Salih et al., 2003; Diermayr
et al., 2007). In chronic myeloid leukemia, the NKG2D/MICA
interaction may participate to the development of an
antitumor response (Salih et al., 2003; Boissel et al., 2006).
However, tumors may impair the NKG2D-mediated response
by shedding MIC molecules expressed on tumor cells with
production of high levels of soluble MICA and/or MICB, in
addition to initiating NKG2D downregulation (Groh et al.,
2002; Salih et al., 2003; Coudert and Held, 2006).
Previous results indicate that Sezary malignant cells are
susceptible to NK lysis from activated autologous NK cells
(Bouaziz et al., 2005). In analyzing the expression of NKG2D-L
on SS tumor cells as well as the expression and function of
NKG2D on effector lymphocytes in SS patients, we determined
whether the malignant cells could induce NK-mediated
immune response through NKG2D/NKG2D-L interactions.
RESULTS AND DISCUSSION
Sezary tumor cells express some NKG2D-L
The staining of CD158k on the surface of tumor cells is
consistent with previous data (Ortonne et al., 2006; Bahler
et al., 2008). In addition, we show here the expression
of NKG2D-L in contrast to normal healthy CD4þ T cells
(Figure 1). We determined, in 10 patients, expression of
MICA, MICB, ULBP, and DNAM-1 ligand poliovirus receptor
CD155, using flow cytometry analysis by specifically gating
the KIR3DL2/CD158kþ tumor cells (Figure 1b and c). Nine
patients expressed at least one NKG2D-L. Sezary cells were
primarily positive for ULBP-2 or ULBP-3 and 3 out of 10
tumors presented both. MICA, MICB, and ULBP-1 were
expressed on some Sezary tumors as well as CD155. Only
one patient expressed all of the NKG2D-L. HLA class I
molecules were detected on all SS tumor cells with similar
levels as opposed to peripheral blood mononuclear cells
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Figure 1. Expression of NKG2D-L on SS tumor cells and sMICA in patient’s sera. (a) Ex vivo CD158k/e staining of CD4þ T lymphocytes in one HD and one
patient (filled histogram). In the Sezary patient, CD158k/e expression was compared to CD4 T cells (empty histogram). (b) Ex vivo phenotype profile on
CD158kþ tumor cells from one representative patient (no. 3) as compared to CD4þ T cells in one HD. Expressions were compared on CD4þCD158kþ tumor
cells (filled histogram) and on the CD158k lymphocytes (empty histogram). (c) NKG2D-L and CD155 expression profiles were analyzed in 10 SS patients.
Numbers indicate the median of fluorescence intensity for each marker. A grey box shows the positive signal defined as superior by at least 1.5-fold to the
isotype control. Concentrations of sMICA and frequency of tumor cells in lymphocytes have been indicated when available. (d) Concentrations of sMICA in sera
from patients (n¼ 10) and HD (n¼ 21) were significantly increased in SS patients; nd, not determined.
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(PBMC) from healthy donors (data not shown). Production of
soluble forms of MICA (sMICA) by tumors may constitute a
mechanism to escape the immune system (Groh et al., 2002;
Salih et al., 2003), for this reason we quantified the levels of
sMICA in patients’ sera in a comparison to healthy donors
(HDs; Figure 1c and d). Sezary patient’s sera were signifi-
cantly more enriched in sMICA as compared to HD (medians:
222.7 and 108.67 pg/ml, respectively, P¼ 0.0035). Although
increased sMICA levels did not directly correlate with MICA
expression on the tumor, we observed that patients with
MICAþ tumors (n¼ 2) had the highest sMICA concentrations
(383.41 and 281.62 pgml1; Figure 1c).
NKG2D expression on NK and T CD8þ lymphocytes of Sezary
patients
NK and T lymphocytes express a panel of activating receptors
such as NKG2D, DNAM-1, and the natural cytotoxicity
receptors (NKp30, NKp44, and NKp46), the latter commonly
being absent on T lymphocytes. Downregulation of such
receptors in SS patients might impair the antitumor response.
NK lymphocytes defined as CD3CD56þ lymphocytes and T
CD8þ (which altogether may represent less than 1% of
PBMC besides the CD4þCD158kþ malignant cells; Table 1)
were phenotyped by flow cytometry in six SS blood samples.
All receptors were expressed on NK cells, whereas only
NKG2D and DNAM-1 were expressed by CD8þ T cells
(Table 1; Figure 2a). Levels of expression showed a broad
variability with, in some cases, a severe downregulation of
NKG2D (patients 2 and 6), DNAM-1 (patient 4), or NKp30
and NKp46 (patient 2). Although median levels were not
significantly different between HD and SS patients, these
observations might be of importance in the context of an
individual antitumor response. In contrast, NKp44 expression
seemed to be increased in three out of four patients tested,
probably indicating the activated status of NK cells (Vitale
et al., 1998). NKG2D expression on CD8þ T cells was less
variable than on NK lymphocytes. Interestingly, patients with
reduced NKG2D expression on NK cells kept a normal
expression on CD8þ T lymphocytes (Figure 2c), highlighting
the differences in the regulation of NKG2D expression in
both lymphocyte populations. There was no correlation
between the expression of NKG2D and the frequency of
tumor cells in the periphery or the levels of sMICA. However,
sMICA is not the only mechanism for the tumor to escape the
NK immune response. Indeed, the high expression of
NKG2D-L on tissues may induce the downregulation of
NKG2D (Oppenheim et al., 2005) and therefore may
constitute for tumors with high invasive rate an efficient
mechanism to repress antitumor activity. Tissue growth
factor-b is also known to downregulate NKG2D expression
on NK cells in concordance with a direct impact on NK
activity against tumor cells in human (Lee et al., 2004).
However, quantification of tissue growth factor-b in Sezary
patients’ sera (median: 36.66 pgml1 (4.55–43.95 pgml1))
was similar to HD (29.34 pgml1 (23.89–39.19 pgml1)).
Sezary tumor cells activate NK cell degranulation
The degranulation of perforin and granzymes by NK cells can
be assessed by detecting the cell-surface expression of the
lysosomal-associated membrane protein CD107a, in a flow
cytometry-based assay (Bryceson et al., 2005). The detection
of CD107a correlates with the lysis of the target by effector
cells (Bryceson et al., 2005). To analyze the sensitivity of ex
vivo freshly isolated Sezary lymphocytes through the
recognition of NKG2D-L, we used the NK cell line NKL in
CD107a mobilization assays. NKL was chosen because of its
high expression of NKG2D with a minimal expression of
natural cytotoxicity receptors (Boissel et al., 2006; data not
shown). In presence of the Sezary tumor cells (n¼ 5), about
8% of NKL cells mobilized of CD107a on their surface,
which is equivalent to the degranulation against the class I
negative NK target keratin 562 (K562; Figure 3a). This
Table 1. Frequency of marker+ cells in Sezary syndrome patients (n=6) and healthy donors (n=21)
Patients no. HD
1 2(%) 3 4(%) 5(%) 6 Median(%) Median(%)
CD3CD56+ NK cells
NK cells/lymphocytes 3.9% 2.0 6.3% 0.1 0.8 0.4% 2.3 3.8
NKG2D+/NK cells 49.8% 25.6 90.2% 77.9 65.3 22.6% 57.6 53.7
NKp30+/NK cells ND 1.2 ND 39.2 43.3 27.4% 33.3 31.5
NKp44+/NK cells ND 0.6 ND 17.6 15.3 12.2% 13.7 3.3
NKp46+/NK cells ND 2.2 ND 54.4 66.0 26.1% 40.2 51.3
DNAM-1+/NK cells ND 59.1 ND 14.3 69.5 63.4% 61.2 53.6
CD8+ T cells
CD8+/lymphocytes 5.9% 2.5 7.9% 0.9 0.1 1.2% 3.1 17.4
NKG2D+/CD8+ T cells 58.4% 71.7 90.2% 87.6 57.0 79.2% 75.5 62.0
DNAM-1+/CD8+ T cells ND 17.2 ND 42.2 50.0 ND 42.2 36.8
ND: not determined.
www.jidonline.org 361
N Dulphy et al.
NKG2D Ligands on Sezary Tumor Cells
demonstrated the capacity of SS tumor cells to trigger
degranulation in an activated NK cell line.
SS patients’ NK cells can be activated through NKG2D
To investigate the activation of NK cells after NKG2D
engagement in SS patients, we performed a CD107a
degranulation assay coupled with a NKG2D staining (Figure
3b–d). NK cells of SS patients were functional in the
degranulation assay against K562 (Figure 3b and c). More-
over, degranulation was significantly increased against C1R-
MICA as compared to C1R. In parallel, NKG2D expression
was reduced by the interaction of NK cells with MICA-
expressing targets such as K562 or C1R-MICA and not with
C1R (Figure 3d). Altogether, these results illustrated the ability
of NKG2D to specifically trigger SS patient’s NK cells
degranulation.
CONCLUDING REMARKS
This study highlights the potential role of NKG2D/NKG2D-L
interactions in NK immune responses in SS patients. Our
results demonstrated NKG2D-L surface expression on SS
tumors and the ability of SS patient’s NK cells to engage
NKG2D and to be functional against sensitive targets.
However, the obvious inefficiency in vivo of NK cells in
patients underlines the importance of mechanisms used by
the tumor to escape the NK-mediated antitumor response,
such as sMICA production, NKG2D downregulation, or
inhibition through the recognition of self HLA class I
molecules by regulatory NK receptors such as the KIR or
CD9/NKG2A. This provides a rationale to reduce KIR activity
by using specific mAb (Koh et al., 2001) or to increase
NKG2D expression and function of autologous or allogeneic
NK cells, for instance via IL-15 which enhances in vitro NK
activation towards SS malignant targets (Wysocka et al.,
2004). These data also indicate that attempts to induce
expression of MICA/B by chromatin remodeling agents, such
as histone deacetylase inhibitors, as proposed in leukemia
(Diermayr et al., 2007; Kato et al., 2007), may be helpful to
SS patients.
MATERIALS AND METHODS
Patients and blood samples
Blood samples from 17 SS patients were collected in the Department
of Dermatology, Henri Mondor-Albert Chenevier Hospital, Cre´teil,
France. Patients have not been previously treated with chemo-
therapy. All patients presented in the blood dominant T-cell clones
by TCR-g chain analysis with the use of PCR-DGGE and have been
previously described (Ortonne et al., 2006; Marie-Cardine et al.,
2007). Seven samples were analyzed for phenotypes and sMICA,
three patients for phenotypes only and three others to quantify
sMICA. Four patients were added for the functional experiments.
HD’s blood samples were obtained at the Saint-Louis Hospital
Transfusion Center, Paris, France. All patients and healthy controls
gave their informed consent to this study, which was approved by
the Institutional Review Board of the Hospital Henri Mondor, Cre´teil,
France. This work followed the Declaration of Helsinki Principles.
PBMC were isolated from freshly collected blood samples by
density gradient centrifugation using lymphocyte separation medium
(Eurobio, Les Ulis, France) and stored in liquid nitrogen. Sera were
collected after coagulation and centrifugation of blood samples.
Flow cytometry analysis
Immunophenotyping analyses were performed on frozen samples of
PBMC on a BD Biosciences LSR or a FACSCanto II flow cytometer
(Becton Dickinson, Le Pont de Claix, France).
Lymphocyte immunophenotyping was performed in four- or six-
color analysis with the following mAb: CD8-FITC produced by R&D
Systems (Lille, France); NKG2D-PE, NKp30-PE, NKp44-PE, and
NKp46-PE from Beckman Coulter (Villepinte, France); DNAM-1-PE,
CD3-PerCP, CD8-PerCP, CD3-AmCyan, CD4-allophycocyanin,
CD16-PacificBlue, and CD56-allophycocyanin commercialized by
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Figure 2. Expression of activating NK receptors on effector cells in SS
patients and HD. (a) Ex vivo expression profile of activating NK receptors on
CD56þCD3 NK cells in a representative SS patient (no. 5, filled curve) was
compared to the isotype control (empty curve). (b) Frequency of NKG2D-
positive NK and CD8þ T cells in SS patients (n¼6) as compared to HD
(n¼21). Medians for each group are shown as a bar. (c) NKG2D expression
(filled curve) on NK and CD8þ T cells in a representative SS patient (no. 2)
compared to the isotype control (empty curve).
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Becton Dickinson. To study tumor cells, indirect stainings were
combined. Binding of mAbs specific for MICA, MICB, ULBP-1,
ULBP-2, and ULBP-3 (R&D Systems), HLA class I molecules and
CD155 (Beckman Coulter) was revealed with a PE-labelled goat anti-
mouse IgG-specific mAb. CD158k was detected on tumor cells with
the IgM mAb Q66 (Ortonne et al., 2006) together with a FITC-
labelled IgM-specific secondary mAb (Jackson ImmunoResearch,
Soham, UK). CD158k/e has been detected in patients or HD CD4þ
T cells with the IgG mAb AZ158 (Bagot et al., 2001). Both CD158k-
specific mAb were provided by Professor A. Moretta. Proper IgG and
IgM isotype controls were used and the expression of NKG2D-L on
SS tumors was taken as positive when the median of fluorescent
intensity was increased 1.5-fold compared to the isotype control.
ELISA
sMICA was quantified in 80 1C stored patients and HD sera with
ELISA kits provided by Bamomab (Munich, Germany) and according
to manufacturer’s recommendations.
Degranulation assay
To test the ability of patients’ tumor cells to induce NKL
degranulation, target cells K562 and patients’ PBMC were incubated
with the NKL cell line deprived of IL-2 for 2 days before the
experiment. Evaluation of SS patient’s NK cells activity was
performed with unsorted SS peripheral blood lymphocytes thawed
the day before the experiment. Cocultures were performed overnight
at an effector/target ratio of 1/1 at 37 1C, in culture medium in the
presence of CD107a-PE (Becton Dickinson) for the term of the assay.
Thereafter, cells were stained with NKG2D-allophycocyanin, CD3-
PerCP (Beckman Coulter), CD56-allophycocyanin or CD56-Alexa
Fluor 488 (Becton Dickinson) antibodies for 20 minutes on ice. Cells
were then fixed in phosphate-buffered saline-2% paraformaldehyde
and analyzed by flow cytometry. CD107a and NKG2D surface
expressions on effector cells incubated without target were
evaluated as the negative controls of the experiment.
Statistics
Frequencies of cell subsets, sMICA concentrations as well as results
of functional assays in HD and SS patients have been compared
using the Mann–Whitney test.
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